XML 48 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summarized Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
Summarized quarterly data for 2016 and 2015 is as follows:

 
 
 
 
 
 
 
 
 
2016 Quarter Ended
 
March 31
 
June 30
 
September 30
 
December 31(4)
 
(in thousands, except per share amounts)
Revenue
$
9,206

 
$
2,088

 
$
6,570

 
$
10,986

Gross profit
$
1,402

 
$
27

 
$
179

 
$
5,069

Loss from continuing operations
$
(10,220
)
 
$
(18,246
)
 
$
(16,618
)
 
$
(23,602
)
Loss (income) from discontinued operations
$
(169
)
 
$
(582
)
 
$
(379
)
 
$
109

Net loss
$
(10,389
)
 
$
(18,828
)
 
$
(16,997
)
 
$
(23,493
)
Net loss per share, basic and diluted
$
(0.42
)
 
$
(0.76
)
 
$
(0.69
)
 
$
(0.95
)

 
2015 Quarter Ended
 
March 31
 
June 30 (1)
 
September 30 (2)
 
December 31(3)
 
(in thousands, except per share amounts)
Revenue
$
4,614

 
$
7,367

 
$
9,120

 
$
6,081

Gross profit
$
691

 
$
1,564

 
$
1,340

 
$
1,231

Loss from continuing operations
$
(10,165
)
 
$
(6,696
)
 
$
(12,981
)
 
$
(11,862
)
(Loss) income from discontinued operations
$
(12,696
)
 
$
79,160

 
$
(1,635
)
 
$
3,019

Net (loss) income
$
(22,861
)
 
$
72,464

 
$
(14,616
)
 
$
(8,843
)
Net (loss) income per share, basic and diluted
$
(1.19
)
 
$
3.78

 
$
(0.65
)
 
$
(0.36
)


(1)
Net income from discontinued operations included an after-tax gain on sale of the Zohydro ER business of $75.6 million. Net loss from continuing operations included a tax benefit of $6.9 million for this divestiture.
(2)
Net loss from continuing operations included an impairment charge for investments acquired in connection with the sale of the Zohydro ER business of $5.5 million, offset by a $5.5 million tax benefit for this divestiture. Net loss from discontinued operations included an adjustment of $2.5 million to the gain on sale of the Zohydro ER business for incremental income tax expense.
(3)
Net loss from continuing operations included a tax benefit related to the sale of Zohydro ER of $3.5 million. Net income from discontinued operations included an adjustment to increase the gain on sale of Zohydro ER business of $2.3 million, which primarily consisted of derecognition of income tax liability due to a reduction in the applicable tax rate, offset by an accrual of $0.4 million related to contingent consideration.
(4)
Net loss from continuing operations included impairment charges of $8.4 million for long-lived assets associated with the production of Sumavel DosePro and prepaid royalties (See Note 6).